Harald Severin Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harald Severin Hansen has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Gitte Petersen
Department of Pharmacology and Pharmacotherapy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
16 shared publicationsBenny Jensen
Technical University
14 shared publications- Lotte Lauritzen
Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
11 shared publications - Sjurdur Frodi Olsen
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
10 shared publications Birthe Moesgaard
Department of Pharmacology, The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
8 shared publications- Thi Ai Diep
Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
8 shared publications
Latest Publications
- Open Access
- 22 July 2024
- Published by Wiley in Experimental Dermatology
- Vol. 33 (7) , e15141
Metabolomic profiling and accurate diagnosis of basal cell carcinoma by MALDI imaging and machine learning
Basal cell carcinoma (BCC), the most common keratinocyte cancer, presents a substantial public health challenge due to its high prevalence. Traditional diagnostic methods, which rely on visual examination and histopathological analysis, do not include metabolomic data. This exploratory study aims to molecularly characterize BCC and diagnose tumour tissue by applying matrix‐assisted laser desorption ionization mass spectrometry imaging (MALDI‐MSI) and machine learning (ML). BCC tumour development was induced in a mouse model and tissue sections containing BCC (n = 12) were analysed. The study design involved three phases: (i) Model training, (ii) Model validation and (iii) Metabolomic analysis. The ML algorithm was trained on MS data extracted and labelled in accordance with histopathology. An overall classification accuracy of 99.0% was reached for the labelled data. Classification of unlabelled tissue areas aligned with the evaluation of a certified Mohs surgeon for 99.9% of the total tissue area, underscoring the model's high sensitivity and specificity in identifying BCC. Tentative metabolite identifications were assigned to 189 signals of importance for the recognition of BCC, each indicating a potential tumour marker of diagnostic value. These findings demonstrate the potential for MALDI‐MSI coupled with ML to characterize the metabolomic profile of BCC and to diagnose tumour tissue with high sensitivity and specificity. Further studies are needed to explore the potential of implementing integrated MS and automated analyses in the clinical setting.
- 22 July 2024
- Published by Wiley in Experimental Dermatology
- Vol. 33 (7) , e15141
Open AccessMetabolomic profiling and accurate diagnosis of basal cell carcinoma by MALDI imaging and machine learning
Basal cell carcinoma (BCC), the most common keratinocyte cancer, presents a substantial public health challenge due to its high prevalence. Traditional diagnostic methods, which rely on visual examination and histopathological analysis, do not include metabolomic data. This exploratory study aims to molecularly characterize BCC and diagnose tumour tissue by applying matrix‐assisted laser desorption ionization mass spectrometry imaging (MALDI‐MSI) and machine learning (ML). BCC tumour development was induced in a mouse model and tissue sections containing BCC (n = 12) were analysed. The study design involved three phases: (i) Model training, (ii) Model validation and (iii) Metabolomic analysis. The ML algorithm was trained on MS data extracted and labelled in accordance with histopathology. An overall classification accuracy of 99.0% was reached for the labelled data. Classification of unlabelled tissue areas aligned with the evaluation of a certified Mohs surgeon for 99.9% of the total tissue area, underscoring the model's high sensitivity and specificity in identifying BCC. Tentative metabolite identifications were assigned to 189 signals of importance for the recognition of BCC, each indicating a potential tumour marker of diagnostic value. These findings demonstrate the potential for MALDI‐MSI coupled with ML to characterize the metabolomic profile of BCC and to diagnose tumour tissue with high sensitivity and specificity. Further studies are needed to explore the potential of implementing integrated MS and automated analyses in the clinical setting.
- 1 May 2021
- Published by Elsevier in Physiology & Behavior
- Vol. 234, 113315
Post-oral fat-induced satiation is mediated by endogenous CCK and GLP-1 in a fat self-administration mouse model
- 1 May 2021
- Published by Elsevier in Physiology & Behavior
- Vol. 234, 113315
Post-oral fat-induced satiation is mediated by endogenous CCK and GLP-1 in a fat self-administration mouse model
- Open Access
- 1 April 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (17) , 6692
Essentiality of n-6 fatty acids
- 1 April 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (17) , 6692
Open AccessEssentiality of n-6 fatty acids
- 2 April 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (10) , 1443-1454
Non‐endocannabinoid N‐acylethanolamines and 2‐monoacylglycerols in the intestine
This review focuses on recent findings of the physiological and pharmacological role of non‐endocannabinoid N‐acylethanolamines (NAEs) and 2‐monoacylglycerols (2‐MAGs) in the intestine and their involvement in the gut‐brain signalling. Dietary fat suppresses food intake, and much research concerns the known gut peptides, for example, glucagon‐like peptide‐1 (GLP‐1) and cholecystokinin (CCK). NAEs and 2‐MAGs represent another class of local gut signals most probably involved in the regulation of food intake. We discuss the putative biosynthetic pathways and targets of NAEs in the intestine as well as their anorectic role and changes in intestinal levels depending on the dietary status. NAEs can activate the transcription factor PPARα, but studies to evaluate the role of endogenous NAEs are generally lacking. Finally, we review the role of diet‐derived 2‐MAGs in the secretion of anorectic gut peptides via activation of GPR119. Both PPARα and GPR119 have potential as pharmacological targets for the treatment of obesity and the former for treatment of intestinal inflammation.Linked Articles: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc
- 2 April 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (10) , 1443-1454
Non‐endocannabinoid N‐acylethanolamines and 2‐monoacylglycerols in the intestine
This review focuses on recent findings of the physiological and pharmacological role of non‐endocannabinoid N‐acylethanolamines (NAEs) and 2‐monoacylglycerols (2‐MAGs) in the intestine and their involvement in the gut‐brain signalling. Dietary fat suppresses food intake, and much research concerns the known gut peptides, for example, glucagon‐like peptide‐1 (GLP‐1) and cholecystokinin (CCK). NAEs and 2‐MAGs represent another class of local gut signals most probably involved in the regulation of food intake. We discuss the putative biosynthetic pathways and targets of NAEs in the intestine as well as their anorectic role and changes in intestinal levels depending on the dietary status. NAEs can activate the transcription factor PPARα, but studies to evaluate the role of endogenous NAEs are generally lacking. Finally, we review the role of diet‐derived 2‐MAGs in the secretion of anorectic gut peptides via activation of GPR119. Both PPARα and GPR119 have potential as pharmacological targets for the treatment of obesity and the former for treatment of intestinal inflammation.Linked Articles: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc
- Open Access
- 22 December 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 39571
Mass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia
Focal cerebral ischaemia has an initial phase of inflammation and tissue injury followed by a later phase of resolution and repair. Mass spectrometry imaging (desorption electrospray ionization and matrix assisted laser desorption ionization) was applied on brain sections from mice 2 h, 24 h, 5d, 7d, and 20d after permanent focal cerebral ischaemia. Within 24 h, N-acyl-phosphatidylethanolamines, lysophosphatidylcholine, and ceramide accumulated, while sphingomyelin disappeared. At the later resolution stages, bis(monoacylglycero)phosphate (BMP(22:6/22:6)), 2-arachidonoyl-glycerol, ceramide-phosphate, sphingosine-1-phosphate, lysophosphatidylserine, and cholesteryl ester appeared. At day 5 to 7, dihydroxy derivates of docosahexaenoic and docosapentaenoic acid, some of which may be pro-resolving mediators, e.g. resolvins, were found in the injured area, and BMP(22:6/22:6) co-localized with the macrophage biomarker CD11b, and probably with cholesteryl ester. Mass spectrometry imaging can visualize spatiotemporal changes in the lipidome during the progression and resolution of focal cerebral inflammation and suggests that BMP(22:6/22:6) and N-acyl-phosphatidylethanolamines can be used as biomarkers for phagocytizing macrophages/microglia cells and dead neurones, respectively.
- 22 December 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 39571
Open AccessMass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia
Focal cerebral ischaemia has an initial phase of inflammation and tissue injury followed by a later phase of resolution and repair. Mass spectrometry imaging (desorption electrospray ionization and matrix assisted laser desorption ionization) was applied on brain sections from mice 2 h, 24 h, 5d, 7d, and 20d after permanent focal cerebral ischaemia. Within 24 h, N-acyl-phosphatidylethanolamines, lysophosphatidylcholine, and ceramide accumulated, while sphingomyelin disappeared. At the later resolution stages, bis(monoacylglycero)phosphate (BMP(22:6/22:6)), 2-arachidonoyl-glycerol, ceramide-phosphate, sphingosine-1-phosphate, lysophosphatidylserine, and cholesteryl ester appeared. At day 5 to 7, dihydroxy derivates of docosahexaenoic and docosapentaenoic acid, some of which may be pro-resolving mediators, e.g. resolvins, were found in the injured area, and BMP(22:6/22:6) co-localized with the macrophage biomarker CD11b, and probably with cholesteryl ester. Mass spectrometry imaging can visualize spatiotemporal changes in the lipidome during the progression and resolution of focal cerebral inflammation and suggests that BMP(22:6/22:6) and N-acyl-phosphatidylethanolamines can be used as biomarkers for phagocytizing macrophages/microglia cells and dead neurones, respectively.
- Open Access
- 1 November 2016
- Published by Elsevier in Biochemical Pharmacology
- Vol. 119, 66-75
Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119
- 1 November 2016
- Published by Elsevier in Biochemical Pharmacology
- Vol. 119, 66-75
Open AccessBiased signaling of lipids and allosteric actions of synthetic molecules for GPR119
- 14 June 2016
- Published by Wiley in BioFactors
- Vol. 42 (6) , 665-673
Oral 2‐oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor
The intestinal G protein‐coupled receptor GPR119 is a novel metabolic target involving glucagon‐like peptide‐1 (GLP‐1)‐derived insulin‐regulated glucose homeostasis. Endogenous and diet‐derived lipids, including N‐acylethanolamines and 2‐monoacylglycerols (2‐MAG) activate GPR119. The purpose of this work is to evaluate whether 2‐oleoyl glycerol (2‐OG) improves glucose tolerance through GPR119, using wild type (WT) and GPR 119 knock out (KO) mice. We here show that GPR119 is essential for 2‐OG‐mediated release of GLP‐1 and CCK from GLUTag cells, since a GPR119 specific antagonist completely abolished the hormone release. Similarly, in isolated primary colonic crypt cultures from WT mice, GPR119 was required for 2‐OG‐stimulated GLP‐1 release while there was no response in crypts from KO mice. In vivo, gavage with 2‐oleyl glyceryl ether ((2‐OG ether), a stable 2‐OG analog with a potency of 5.3 µM for GPR119 with respect to cAMP formation as compared to 2.3 µM for 2‐OG), significantly (P < 0.05) improved glucose clearance in WT littermates, but not in GPR119 KO mice. Finally, deletion of GPR119 in mice resulted in lower glucagon levels, whereas the levels of insulin and GIP were unchanged. In the present study we show that 2‐OG stimulates GLP‐1 secretion through GPR119 activation in vitro, and that fat‐derived 2‐MAGs are potent candidates for mediating fat‐induced GLP‐1 release through GPR119 in vivo. © 2016 BioFactors, 42(6):665–673, 2016
- 14 June 2016
- Published by Wiley in BioFactors
- Vol. 42 (6) , 665-673
Oral 2‐oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor
The intestinal G protein‐coupled receptor GPR119 is a novel metabolic target involving glucagon‐like peptide‐1 (GLP‐1)‐derived insulin‐regulated glucose homeostasis. Endogenous and diet‐derived lipids, including N‐acylethanolamines and 2‐monoacylglycerols (2‐MAG) activate GPR119. The purpose of this work is to evaluate whether 2‐oleoyl glycerol (2‐OG) improves glucose tolerance through GPR119, using wild type (WT) and GPR 119 knock out (KO) mice. We here show that GPR119 is essential for 2‐OG‐mediated release of GLP‐1 and CCK from GLUTag cells, since a GPR119 specific antagonist completely abolished the hormone release. Similarly, in isolated primary colonic crypt cultures from WT mice, GPR119 was required for 2‐OG‐stimulated GLP‐1 release while there was no response in crypts from KO mice. In vivo, gavage with 2‐oleyl glyceryl ether ((2‐OG ether), a stable 2‐OG analog with a potency of 5.3 µM for GPR119 with respect to cAMP formation as compared to 2.3 µM for 2‐OG), significantly (P < 0.05) improved glucose clearance in WT littermates, but not in GPR119 KO mice. Finally, deletion of GPR119 in mice resulted in lower glucagon levels, whereas the levels of insulin and GIP were unchanged. In the present study we show that 2‐OG stimulates GLP‐1 secretion through GPR119 activation in vitro, and that fat‐derived 2‐MAGs are potent candidates for mediating fat‐induced GLP‐1 release through GPR119 in vivo. © 2016 BioFactors, 42(6):665–673, 2016
- 1 September 2015
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 102 (3) , 548-555
The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans
Background: Dietary triglycerides can, after digestion, stimulate the intestinal release of incretin hormones through activation of G protein–coupled
- 1 September 2015
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 102 (3) , 548-555
The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans
Background: Dietary triglycerides can, after digestion, stimulate the intestinal release of incretin hormones through activation of G protein–coupled
- 30 October 2014
- Published by Wiley in BioFactors
- Vol. 40 (6) , 596-602
Evaluation of the immediate vascular stability of lipoprotein lipase‐generated 2‐monoacylglycerol in mice
2‐Monoacylglycerols are gaining increasing interest as signaling lipids, beyond endocannabinoids, for example, as ligands for the receptor GPR119 and as mediators of insulin secretion. In the vascular system, they are formed by the action of lipoprotein lipase (LPL); however, their further disposition is unclear. Assuming similar affinity for uptake and incorporation into tissues of 2‐oleoylglycerol and 2‐oleylglyceryl ether, we have synthesized a3H‐labeled 2‐ether analog of triolein (labeled in alkyl group) and compared its disposition with14C‐labeled triolein (labeled in glycerol) 20 min after intravenous coadministration in a ratio of 1:1 to mice. We found that peripheral tissues and the liver in particular are able to take up 2‐monoacylglycerols as seen from3H uptake. In muscle and adipose tissue, 2‐monoacylglycerols are probably further hydrolyzed as seen by an increased3H/14C ratio, whereas in the liver and the heart, data suggest that they are also subjected to re‐esterification to triacylglycerol, as seen by an unchanged3H/14C ratio in the lipid fraction of the tissues. Our findings suggest that LPL‐generated 2‐monoacylglycerol is likely to be stable in the vascular system and thus have a potential to circulate or at least exert effects in tissues where it may be locally produced. © 2014 BioFactors, 40(6):596–602, 2014
- 30 October 2014
- Published by Wiley in BioFactors
- Vol. 40 (6) , 596-602
Evaluation of the immediate vascular stability of lipoprotein lipase‐generated 2‐monoacylglycerol in mice
2‐Monoacylglycerols are gaining increasing interest as signaling lipids, beyond endocannabinoids, for example, as ligands for the receptor GPR119 and as mediators of insulin secretion. In the vascular system, they are formed by the action of lipoprotein lipase (LPL); however, their further disposition is unclear. Assuming similar affinity for uptake and incorporation into tissues of 2‐oleoylglycerol and 2‐oleylglyceryl ether, we have synthesized a3H‐labeled 2‐ether analog of triolein (labeled in alkyl group) and compared its disposition with14C‐labeled triolein (labeled in glycerol) 20 min after intravenous coadministration in a ratio of 1:1 to mice. We found that peripheral tissues and the liver in particular are able to take up 2‐monoacylglycerols as seen from3H uptake. In muscle and adipose tissue, 2‐monoacylglycerols are probably further hydrolyzed as seen by an increased3H/14C ratio, whereas in the liver and the heart, data suggest that they are also subjected to re‐esterification to triacylglycerol, as seen by an unchanged3H/14C ratio in the lipid fraction of the tissues. Our findings suggest that LPL‐generated 2‐monoacylglycerol is likely to be stable in the vascular system and thus have a potential to circulate or at least exert effects in tissues where it may be locally produced. © 2014 BioFactors, 40(6):596–602, 2014
- 1 August 2014
- Published by Elsevier in Pharmacological Research
- Vol. 86, 18-25
Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat
- 1 August 2014
- Published by Elsevier in Pharmacological Research
- Vol. 86, 18-25
Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat